[go: up one dir, main page]

SI1874341T1 - Eritrociti, vsebujoči deiminazo arginina - Google Patents

Eritrociti, vsebujoči deiminazo arginina

Info

Publication number
SI1874341T1
SI1874341T1 SI200630327T SI200630327T SI1874341T1 SI 1874341 T1 SI1874341 T1 SI 1874341T1 SI 200630327 T SI200630327 T SI 200630327T SI 200630327 T SI200630327 T SI 200630327T SI 1874341 T1 SI1874341 T1 SI 1874341T1
Authority
SI
Slovenia
Prior art keywords
containing arginine
erythrocytes containing
deimination
erythrocytes
arginine deimination
Prior art date
Application number
SI200630327T
Other languages
English (en)
Inventor
Yann Godfrin
Pierre-Olivier Goineau
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of SI1874341T1 publication Critical patent/SI1874341T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200630327T 2005-04-25 2006-04-25 Eritrociti, vsebujoči deiminazo arginina SI1874341T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504122A FR2884717B1 (fr) 2005-04-25 2005-04-25 Erythrocytes renfermant de l'arginine deiminase
EP06744562A EP1874341B1 (en) 2005-04-25 2006-04-25 Erythrocytes containing arginine deiminase

Publications (1)

Publication Number Publication Date
SI1874341T1 true SI1874341T1 (sl) 2009-08-31

Family

ID=35787979

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630327T SI1874341T1 (sl) 2005-04-25 2006-04-25 Eritrociti, vsebujoči deiminazo arginina

Country Status (17)

Country Link
US (2) US9125876B2 (sl)
EP (1) EP1874341B1 (sl)
JP (1) JP5339899B2 (sl)
KR (1) KR101431650B1 (sl)
CN (1) CN101163497B (sl)
AT (1) ATE432711T1 (sl)
AU (1) AU2006238917C1 (sl)
CA (1) CA2606420C (sl)
CY (1) CY1109353T1 (sl)
DE (1) DE602006007122D1 (sl)
DK (1) DK1874341T3 (sl)
ES (1) ES2326549T3 (sl)
FR (1) FR2884717B1 (sl)
PL (1) PL1874341T3 (sl)
PT (1) PT1874341E (sl)
SI (1) SI1874341T1 (sl)
WO (1) WO2006114691A1 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
EP2242507B1 (en) * 2008-02-13 2013-02-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9033948B2 (en) * 2011-04-19 2015-05-19 Fenwel, Inc. Single collection bag blood collection system, method and apparatus
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EA201691686A1 (ru) 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
RS62939B1 (sr) 2016-01-11 2022-03-31 Rubius Therapeutics Inc Kompozicije i metode u vezi sa multimodalnim terapijskim ćelijskim sistemima u indikacijama kancera
IL262677B2 (en) 2016-05-03 2025-08-01 Sqz Biotechnologies Co Intracellular delivery of biomolecules to suppress an immune response or to induce tolerance to an antigen in an individual
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
CN113750232B (zh) * 2021-09-12 2023-06-02 重庆医科大学 一种巨噬细胞膜包覆精氨酸脱亚胺酶/过氧化氢酶/ir780纳米粒、制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051382A (sl) * 1900-01-01
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPH0235081A (ja) 1988-07-26 1990-02-05 Agency Of Ind Science & Technol アルギニン・デイミナーゼおよびその用途
JPH0253490A (ja) 1988-08-16 1990-02-22 Agency Of Ind Science & Technol アルギニン・デイミナーゼ遺伝子
DE58908768D1 (de) * 1988-09-30 1995-01-26 Siemens Ag Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens.
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
JP3004788B2 (ja) 1991-10-28 2000-01-31 株式会社ジャパンエナジー アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
AU680890B2 (en) * 1993-03-23 1997-08-14 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
KR100406268B1 (ko) 1999-12-24 2003-11-19 주식회사 안지오랩 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
AU2001289132A1 (en) * 2000-11-28 2002-06-11 Phoenix Pharmacologics, Inc. Modified arginine deiminase
JP4733393B2 (ja) * 2002-11-18 2011-07-27 ポラリス・グループ インビボでウイルス複製を阻害する方法
US20070105220A1 (en) * 2003-08-06 2007-05-10 The Regents Of The University Of California Erythrocytic cells and method for loading solutes

Also Published As

Publication number Publication date
ES2326549T3 (es) 2009-10-14
KR101431650B1 (ko) 2014-08-20
JP5339899B2 (ja) 2013-11-13
JP2008538761A (ja) 2008-11-06
AU2006238917B2 (en) 2011-04-07
US20160030532A1 (en) 2016-02-04
FR2884717A1 (fr) 2006-10-27
US9968663B2 (en) 2018-05-15
EP1874341A1 (en) 2008-01-09
CN101163497B (zh) 2012-12-19
CY1109353T1 (el) 2014-07-02
PL1874341T3 (pl) 2009-12-31
HK1112187A1 (en) 2008-08-29
AU2006238917C1 (en) 2011-08-04
KR20080000678A (ko) 2008-01-02
US9125876B2 (en) 2015-09-08
FR2884717B1 (fr) 2009-07-03
EP1874341B1 (en) 2009-06-03
ATE432711T1 (de) 2009-06-15
WO2006114691A1 (en) 2006-11-02
DE602006007122D1 (de) 2009-07-16
DK1874341T3 (da) 2009-08-03
CN101163497A (zh) 2008-04-16
PT1874341E (pt) 2009-07-21
AU2006238917A1 (en) 2006-11-02
CA2606420C (en) 2015-01-27
CA2606420A1 (en) 2006-11-02
US20080274092A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
SI1874341T1 (sl) Eritrociti, vsebujoči deiminazo arginina
Pader et al. Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase
ATE508190T1 (de) Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
BRPI0508470A (pt) sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
WO2011035001A3 (en) Novel heparin entities and methods of use
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
EA200970397A1 (ru) Ингибиторы трипсинподобной серинпротеазы, их получение и применение
WO2007048042A3 (en) Small molecule inhibitors of hiv-1 capsid assembly
WO2006095259A3 (en) Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
WO2008054534A3 (en) Screening systems utilizing rtp801
Yu et al. Prodrugs of persulfides, sulfur dioxide, and carbon disulfide: important tools for studying sulfur signaling at various oxidation states
WO2008106594A3 (en) Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis
Wang et al. Inhibition of endoplasmic reticulum stress cooperates with SLC7A11 to promote disulfidptosis and suppress tumor growth upon glucose limitation
CY1113525T1 (el) Θεραπεια στοχευσης καθεψινης s
CY1118302T1 (el) Λωριδα χαρτιου για τον καθορισμο των ελαχιστων ανασταλτικων συγκεντρωσεων αντιβιοτικων
Banno et al. Identification of 3-aminomethyl-1, 2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554
EA200870434A1 (ru) Аминопроизводные андростанов и андростенов как лекарственные средства против сердечно-сосудистых нарушений
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
EA200800357A1 (ru) Новые фармацевтические соединения
ATE485261T1 (de) Salicylsäurederivate
ATE474567T1 (de) Kombinationspräparate enthaltend 2- methylthiazolidin-2,4-dicarbonsäure
Kinoshita Effects of oxidative stress on vascular function, and the role of anesthetics
WO2008073634A3 (en) Compositions and methods for detecting and treating endothelial dysfunction